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Abstract
Background: Adipose-derived stem cells (ASCs) have been introduced as an alternative to bone marrow mesenchymal
stem cells (BMSCs) for cell-based therapy. However, different studies comparing ASCs and BMSCs have shown conflicting
results. In fact, harvesting ASCs and BMSCs from different individuals might influence the results, making comparison
difficult. Therefore, this study aimed to characterize donor-matched ASCs and BMSCs in order to investigate proliferation,
differentiation potential and possible effects of donor variation on these mesenchymal stem cells (MSCs).
Methods: Human bone marrow and adipose tissue samples were obtained from nine donors aged 8–14. ASCs and
BMSCs were isolated and characterized based on expression of surface markers using flow cytometry. The proliferation
up to 21 days was investigated. Multi-lineage differentiation was induced using osteogenic, chondrogenic and
adipogenic differentiation media. Alkaline phosphatase (ALP) activity was monitored and collagen type I formation was
evaluated by immunofluorescence staining. In vitro multi-potency was studied using tissue-specific stains and lineage-
specific gene expression. In addition, the osteogenic lineage was evaluated at protein level.
Results: Isolated ASCs and BMSCs from all donors demonstrated morphologic and immunophenotypic characteristics
of MSCs, with expression of MSCs markers and negative expression of hematopoietic markers. Unlike BMSCs, ASCs
showed high expression of CD49d and low expression of Stro-1. In general, ASCs showed significantly higher
proliferation and adipogenic capacity with more lipid vesicle formation and expression of the adipogenesis-related
genes than BMSCs. In contrast, BMSCs showed significantly higher osteogenic and chondrogenic capacity compared
to ASCs. BMSCs had earlier and higher ALP activity, calcium deposition, and expression of the osteogenesis- and
chondrogenesis-related genes and the osteogenesis-related protein osteopontin. Proliferation and differentiation
capacity of ASCs and BMSCs varied significantly among the donors.
Conclusions: ASCs and BMSCs showed tissue-specific differentiation abilities, but with significant variation between
donors. The similarities and differences in the properties of ASCs and BMSCs should be taken into consideration when
planning stem cell-based therapy.
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Background
Stem cell-based therapy has emerged as an alternative
strategy in bone tissue engineering to overcome the limita-
tions of autologous bone grafting. These limitations include
donor site morbidity, risk of infection, nerve damage and
hemorrhage [1]. Adult mesenchymal stem cells (MSCs) are
undifferentiated multipotent cells characterized by the cap-
acity for self-renewal and the ability to differentiate into
various cells of mesenchymal origin, including adipocytes,
chondrocytes, myocytes and osteoblasts, when exposed to
specific growth signals [2]. MSCs can be obtained from dif-
ferent sources, including bone marrow, adipose tissue, den-
tal pulp, synovium, muscle and other tissues [3]. The
International Society for Cellular Therapy (ISCT) proposed
that MSCs must be plastic-adherent (e.g. to a tissue culture
flask), must express the surface markers CD73, CD90 and
CD105 (≥ 90%), not express the hematopoietic markers
CD14, CD34, CD45, CD19 and HLA-DR (≤ 2%), and
should be able to undergo multi-lineage differentiation
(osteogenic, adipogenic and chondrogenic) [4].
Bone marrow mesenchymal stem cells (BMSCs) have
been the most extensively used and investigated MSCs.
However, harvesting BMSCs has limitations due to the
possible pain and morbidity associated with the bone mar-
row aspiration procedure and the limited number of MSCs
obtained, as only a relatively small amount (0.001–0.01%)
of the harvested bone marrow cells are MSCs [5]. BMSCs
were also reported to show signs of senescence, early dur-
ing expansion [6]. These issues have caused scientists to
direct their efforts toward investigating alternative and
comparable sources for MSCs. Abundant numbers of
adipose-derived stem cells (ASCs) have been reported to
be easily isolated from adipose tissue by a minimally inva-
sive procedure [7]. In addition, ASCs can be obtained from
adipose tissue from multiple sites [8–11]. Although signifi-
cant biologic differences have been shown in MSCs derived
from different sources [12–14], ASCs and BMSCs have
comparable characteristics when it comes to morphology
and surface proteins [15]. Further, ASCs have the ability to
undergo multi-lineage differentiation, including osteogenic,
chondrogenic, adipogenic, cardiomyocytic, hepatic and
neurogenic differentiation [16]. The proliferation and dif-
ferentiation capacity into different mesenchymal lineages
make ASCs a promising less-invasive alternative to BMSCs
for cell-based therapeutic applications [17, 18].
For bone tissue engineering, many studies have com-
pared the in vitro osteogenic capacity of human BMSCs
and ASCs [13, 18–25]. Some of these studies reported
greater osteogenic capacity of BMSCs than ASCs [21–
24], whereas other studies suggested that ASCs have
equal or superior osteogenic potential compared to
BMSCs [18–20, 25], making ASCs suitable for bone tis-
sue engineering and osteogenic regenerative medicine
[17, 26]. However, the majority of these studies
compared ASCs and BMSCs obtained from different in-
dividuals. The proliferation and differentiation properties
of MSCs obtained from one donor might differ from
MSCs obtained from another donor [27], and age is con-
sidered to affect the properties of MSCs [28]. MSCs ori-
gin may be crucial for potential use in cell-based
therapies. Studying donor-matched BMSCs and ASCs
will result in a more reliable/robust comparison between
these two types of MSCs. Therefore, the present study
aimed to characterize donor-matched ASCs and BMSCs
in order to investigate proliferation, differentiation po-
tential and possible effects of donor variation on these
MSCs.
Methods
Collection of adipose tissue and bone marrow aspirates
Human adipose tissue and bone marrow aspirates were
obtained with informed parental consent from nine pa-
tients aged 8–14 years who had undergone iliac crest
surgery for treatment of cleft lip and palate at the De-
partment for Plastic, Hand and Reconstructive Surgery,
National Fire Damage Center, Bergen, Norway.
Isolation and expansion of human BMSCs
BMSCs were isolated from bone marrow aspirates and
processed as previously described [29], with some modi-
fications. In brief, 10 ml of human bone marrow was as-
pirated from the anterior iliac crest with the patient in a
supine position. The aspiration syringe was loaded with
3000–5000 units heparin (Leo Pharma A/S, Ballerup,
Denmark) to prevent clotting of the marrow sample.
The aspirate was filtered with a 70 μm cell strainer, diluted
1:1 with culture medium [Dulbecco’s Modified Eagle’s
medium (DMEM) (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10% fetal bovine serum (FBS) (Hyclone -
GE Healthcare Life Sciences, South Logan, UT, USA) and
1% antibiotics (penicillin/streptomycin; GE Healthcare
Life Sciences)], and centrifuged at 1800 rpm for 10 min at
room temperature (RT). After supernatant removal, the
cell pellet was suspended in culture medium and plated in
a 75 cm2 culture flask and maintained at 37 °C in a hu-
midified atmosphere containing 5% CO2. After 24 h, cells
were washed with phosphate-buffered saline (PBS) (Invi-
trogen) to remove the non-adherent cells. The culture
medium was then changed twice a week. When 80%
confluence was reached, cells were detached from the cul-
ture flasks using Trypsin/EDTA solution (Lonza, Basel,
Switzerland). Cells were sub-cultured and expanded, using
BMSCs at passage 3–5 for the in vitro assessment. Cell
number and viability of BMSCs were assessed using 0.4%
Trypan blue stain (Invitrogen) and a Countess™ Auto-
mated Cell Counter (Invitrogen). Growth and morphology
of cells were routinely assessed using an inverted micro-
scope (Nikon Eclipse TS100, Tokyo, Japan).
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Isolation and expansion of human ASCs
ASCs were isolated from subcutaneous adipose tissue as
previously described [8]. In brief, adipose tissue block
was extensively washed with PBS containing 5% antibi-
otics. The adipose tissue was minced and digested with
0.1% collagenase type I (Worthington Biochemical Cor-
poration, Lakewood, NJ, USA) in PBS containing 2% an-
tibiotics for 60 min at 37 °C. Collagenase was then
neutralized with an equal amount of culture medium
and centrifuged for 5 min at 2000 rpm. The centrifuga-
tion was repeated, preceded by shaking to disrupt the
pellet, after which supernatant fluid was aspirated. The
remaining pellet was suspended in culture medium,
plated in a 75 cm2 culture flask and maintained at 37 °C
in 5% CO2. Cells were expanded as described above,
using ASCs at passage 3–5 for the in vitro assessment.
Growth and morphology of cells were routinely assessed
using the inverted microscope.
Characterization of ASCs and BMSCs
ASCs and BMSCs characterization by flow cytometry
was performed based on specific surface antigens. The
cells were harvested and incubated with solutions of
fluorescent antibodies, CD34, CD45, CD73, CD90,
CD105, CD49d, HLA-DR (BD Biosciences. San Jose,
CA, USA) and Stro-1 (Santa Cruz Biotechnology, Dallas,
TX, USA) according to the manufacturer’s recommenda-
tions. Briefly, cells (4 × 105) were suspended in 400 μl of
PBS and centrifuged at 10,000 rpm for 5 min at 4 °C,
and 20 μl of blocking reagent [0.5% bovine serum albu-
min (BSA) (Sigma-Aldrich, St Louis, MO, USA) in PBS]
was added to the resulting cell pellet and incubated for
10 min at RT. Fluorescent monoclonal antibodies were
added to each pellet and incubated in the dark for
30 min at 4 °C. Cells were then suspended in PBS, cen-
trifuged at 10,000 rpm for 5 min and washed with PBS
twice, followed by resuspension in 300 μl PBS. Final quan-
tification was performed with a BD LSRFortessa cell
analyzer (BD Biosciences). Stained samples (50,000 events)
were analyzed and compared to the corresponding un-
stained samples. Data were analyzed using flow cytometry
data analysis software (FlowJo V10, Flowjo, LLC, Ashland,
OR, USA).
Assessment of the metabolic activity of the cells
ASCs and BMSCs were cultured in 96-well plates
(NUNC™, Thermo Fisher Scientific, Waltham, MA, USA)
at a seeding density of 3 × 103 cells/cm2 for 3, 7, 14 and
21 days. At each time point, cells were washed with PBS,
and MTT solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide solution (Sigma-Aldrich) in cul-
ture medium (dilution 1:4)] was added. The plates were
incubated for 4 h in a humidified incubator at 37 °C con-
taining 5% CO2. Cells were then fixed with Tris-buffered
formalin for 5 min, washed with distilled water and left to
dry overnight. Dimethyl sulfoxide (DMSO) (Sigma-Al-
drich) was added and each plate was shaken on a plate
shaker for 20 min before the absorbance was read at
570 nm using FLUOstar OPTIMA Microplate Reader
(BMG Labtech, Offenburg, Germany).
Multi-lineage differentiation of ASCs and BMSCs
For osteogenic differentiation, ASCs and BMSCs were
seeded in 12-well plates at a density of 3 × 103 cells/cm2.
After 24 h, ASCs and BMSCs were washed with PBS
and osteogenic differentiation medium was added.
Osteogenic differentiation medium was prepared by
adding 0.05 mM L-ascorbic acid 2-phosphate, 10 nM
dexamethasone and 10 mM β glycerophosphate (all
from Sigma-Aldrich) to the culture medium. ASCs and
BMSCs in routine culture medium served as control.
For chondrogenic differentiation, ASCs and BMSCs were
seeded in 15 ml tubes at a density of 5 × 105 cells to
form a pellet. After 24 h, pellets were washed with PBS
and StemPro® chondrogenic differentiation medium
(Invitrogen) was added. BMSCs and ASCs pellets in rou-
tine culture medium served as control. All media were
changed twice per week for 4 weeks. For adipogenic dif-
ferentiation, ASCs and BMSCs were seeded in 12-well
plates at a density of 7 × 103 cells/cm2. After 24 h, ASCs
and BMSCs were washed with PBS and StemPro® adipo-
genic differentiation medium (Invitrogen) was added.
ASCs and BMSCs in routine culture medium served as
control. Adipogenic and control media were changed
twice per week for 2 weeks.
Alkaline phosphatase (ALP) staining and assay
ASCs and BMSCs in osteogenic and control media were
fixed with paraformaldehyde 4% at day 3, 7 and 14 for
ALP staining, using SIGMAFASTTM BCIP/NBT tablets
(Sigma-Aldrich). Images of the staining were taken using
the inverted microscope. For the ALP assay at day 14,
ASCs and BMSCs were lysed in 0.1% Triton-X100 buffer
(Sigma-Aldrich), followed by two freezing-thawing cycles
at − 80 °C, after which 20 μl of cell lysate was added in
96-well plate and mixed with 90 μl of working solution
containing Sigma 104® phosphatase substrate (Sigma-Al-
drich) and alkaline buffer solution (Sigma-Aldrich). After
incubation at 37 °C for 15 min, 50 μl of NaOH (sodium
hydroxide) was added to stop the reaction. Absorbance
was measured at 405 nm using the microplate reader.
ALP activity assay was presented relative to BMSCs cul-
tured in control medium as control samples.
Immunofluorescence (IF) staining
Expression of collagen type I in ASCs and BMSCs after
14 days in osteogenic and control media was studied by
IF staining. Cells were fixed with 4% paraformaldehyde
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for 15 min at RT, permeabilized with 0.1% Triton X-100
and blocked with 1% BSA in PBS. Cells were incubated
under shaking with rabbit polyclonal anti-collage type I
(Abcam, Cambridge, UK, dilution 1:500) overnight at 4 °
C. Goat anti-rabbit Alexa Fluor 546 IgG was used as sec-
ondary antibody (Life Technologies, Carlsbad, CA, USA,
dilution 1:800). The actin cytoskeleton was simultan-
eously stained for 45 min using phalloidin-Atto488 (Sig-
ma-Aldrich, dilution 1:50). After washing with PBS, the
nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI) (Sigma-Aldrich, dilution 1:2000). Images were
taken using an inverted fluorescent microscope (Nikon
Eclipse Ti, Tokyo, Japan).
Evaluation of proliferation and multi-potency at gene level
Cells in osteogenic (day 7, 14 and 21), chondrogenic
(day 28), adipogenic (day 14) and control media were
harvested for RNA extraction. Total RNA was extracted
using RNA extraction kit (Maxwell®, Promega, Madison,
WI, USA) following the manufacturer’s protocol. Quan-
tity and purity of RNA were determined by Nanodrop
ND-1000 Spectrophotometer (Nanodrop Technologies,
Wilmington, DE, USA). cDNA synthesis was achieved
from 400 ng of total RNA using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s proto-
col. Real-time quantitative polymerase chain reaction
(qPCR) was performed using TaqMan Fast Universal
PCR Master Mix (Applied Biosystems) following the
manufacturer’s protocol. Amplification was performed in
a 96-well thermal cycle plate on StepOne™ Real-Time
PCR System (Applied Biosystems) to detect the gene
expression of the proliferating cell nuclear antigen
(PCNA). The osteogenic genes runt-related transcription
factor 2 (Runx2), collagen type I, ALP and osteopontin,
the chondrogenic gene aggrecan and the adipogenic
genes peroxisome proliferator activated receptor gamma
(PPARG) and lipoprotein lipase (LPL) were used to
evaluate the osteogenic, chondrogenic and adipogenic
differentiation. Glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) was used as an endogenous control. All
gene primers were from Applied Biosystems (Table 1).
Thermo-cycling conditions were 95 °C for 20 s, followed
by 40 cycles at 95 °C for 1 s and 60 °C for 20 s. The ex-
pression of PCNA was presented relative to BMSCs in
routine culture medium at day 7. The expression of the
osteogenic genes Runx2, collagen type I, ALP and osteo-
pontin was presented relative to BMSCs in osteogenic
medium at day 7. The expression of the chondrogenic
gene aggrecan and the adipogenic genes LPL and
PPARG was presented relative to BMSCs in chondro-
genic and adipogenic media, respectively. Data were ana-
lyzed by the 2-ΔΔCT method.
Western blot analysis
For western blot analysis at day 21 in osteogenic medium,
ASCs and BMSCs were lysed in a ready-made 2× laemmli
sample buffer (Bio-Rad Laboratories, Hercules, CA, USA)
supplemented with 2-mercaptoethanol (Sigma-Aldrich).
Homogenates were collected, heated at 95 °C for 5 min
and centrifuged at 16,000 rpm for 1 min. Each sample
(15 μl) was loaded into 10% casted Sodium Dodecyl
Sulfate (SDS)-Polyacrylamide Gel for electrophoresis, and
then blotted to a Polyvinylidene Difluoride (PVDF) mem-
brane (Bio-Rad Laboratories). The membrane was blocked
with 5% skim milk (Sigma-Aldrich) for 1 h at RT, incu-
bated with osteopontin primary antibody (sc-21,742, Santa
Cruz, dilution 1:200) and β-actin antibody (sc-47,778,
Santa Cruz, dilution 1:200) for 2 h at RT, followed by incu-
bation with horseradish peroxidase-conjugated anti IgG
secondary antibody (sc-516,102, Santa Cruz, dilution
1:1000) for 1 h at RT. Protein bands were visualized with
Clarity Max™Western ECL Blotting Substrate (Bio-Rad La-
boratories) using ChemiDoc™ XRS+ system (Bio-Rad
Laboratories).
Evaluation of multi-potency using tissue-specific staining
For osteogenic differentiation, ASCs and BMSCs in
osteogenic and control media were fixed with 4% para-
formaldehyde at day 21 and 28 to evaluate calcium
deposition using Alizarin red S staining. Briefly, after fix-
ation, cells were stained with 2% Alizarin red S (Sig-
ma-Aldrich) solution for 30 min at RT, and then washed
and dried overnight. Images were made using the
inverted microscope. For quantification, the stain was
dissolved in cetylpyridinium chloride (Sigma-Aldrich)
and absorbance was measured using the microplate
reader at 540 nm. For chondrogenic differentiation, ASC
and BMSC pellets in chondrogenic and control media
were fixed with 4% paraformaldehyde at day 28. Alcian
blue staining was used to examine the cartilaginous
Table 1 Real-time qPCR primers
Gene Assay ID Amplicon length
GAPDH GAPDH: Hs 02758991_g1 93
PCNA PCNA: Hs99999177_g1 69
Runx2 RUNX2: Hs01047973_m1 86
Collagen type 1 COL1A2: Hs00164099_m1 68
ALP ALPL: Hs01029144_m1 79
Osteopontin SPP1: Hs00959010_m1 84
Aggrecan ACAN: Hs00153936_m1 91
PPARG PPARG: Hs00234592_m1 77
LPL LPL: Hs00173425_m1 103
ALP alkaline phosphatase, GAPDH glyceraldehyde-3-phosphate dehydrogenase,
LPL lipoprotein lipase, PCNA proliferating cell nuclear antigen, PPARG peroxisome
proliferator activated receptor gamma, qPCR quantitative polymerase chain
reaction, Runx2 runt-related transcription factor 2
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proteoglycan matrix formation. Briefly, cell pellets were
embedded in paraffin and sectioned in 6 μm sections.
Sections were stained with 2% Alcian blue stain (Sig-
ma-Aldrich) in 3% acetic acid solution (Sigma-Aldrich)
for 30 min and a 0.1% nuclear fast red (Sigma-Aldrich)
solution was used as a counterstain. Images were taken
using an upright microscope (Nikon Eclipse 80i, Tokyo,
Japan). For adipogenic differentiation, ASCs and BMSCs
in adipogenic and control media were fixed with 4%
paraformaldehyde at day 14 to assess intracellular lipid
vesicles using Oil red O staining. Briefly, 60% isopropa-
nol (Sigma-Aldrich) was added to the wells and incu-
bated for 5 min at RT. The isopropanol was removed
and cells were stained with 0.3% Oil red O (Sigma-Al-
drich) for 15 min. After washing, hematoxylin was added
for 1 min to counterstain the cells before imaging, using
the inverted microscope. The stain was then extracted
using 99% isopropanol (Sigma-Aldrich) and quantified
using the microplate reader at 540 nm absorbance.
Statistics
Mixed-effects models for continuous data were applied
for the statistical analyses. Since donor-matched ASCs
and BMSCs were obtained from nine donors, donor was
included in the models as a random effect. The results
from the mixed models are shown in the figures as mean
values with standard errors. Each donor is represented
in the figures by a symbol (Table 2). P values less than
0.05 were considered statistically significant and are in-
dicated by an asterisk in figures and tables illustrating
the results. Intra-class correlations (ICC), based on the
mixed models, were calculated to estimate the effect of
donor on both types of cells. Data were analyzed using
STATA (version 15, StataCorp, College Station, TX,
USA).
Results
ASCs and BMSCs shared a similar morphology and
immunophenotype with small differences
ASCs and BMSCs were successfully isolated from the
nine donors. Cells adhered to the plastic culture flask
and were identified as ASCs and BMSCs ≈ 2 and ≈ 4 days
after plating, respectively. ASCs and BMSCs showed a
fibroblast-like cell morphology. After passage 0, ASCs
reached 80% confluence after ≈ 6 days, compared to ≈
8 days for BMSCs. During sub-culturing up to passage 5,
no morphologic or growth pattern changes were ob-
served (Fig. 1a). The stem cell markers CD73, CD90,
and CD105 were generally highly expressed (> 90%) in
ASCs and BMSCs, but the expression of these markers
was less than 90% in ASCs in two of nine donors and in
BMSCs in one of nine donors. ASCs and BMSCs had
negative expression (≤ 2%) of the hematopoietic markers
CD45 and HLA-DR, except for ASCs in one of nine do-
nors. While BMSCs demonstrated negative expression
(≤ 2%) of CD34, the average expression of this marker
was significantly higher in ASCs (p < 0.01), and only
ASCs in four of nine donors had expression ≤ 2%. The
expression of CD49d in ASCs was significantly higher
than in BMSCs (p < 0.001), which showed low expres-
sion (10–50%) in nine of nine donors. On average, there
was a significant difference in the expression of Stro-1 in
favor of BMSCs compared to ASCs (p < 0.05), but ASCs
in one of nine donor demonstrated higher expression
and the expression was almost similar in three of nine
donors (Fig. 1b-d).
ASCs continued to proliferate up to 21 days, but not
BMSCs
The MTT proliferation assay and expression of PCNA
gene showed variability in the proliferation rate of ASCs
and BMSCs among different donors (Fig. 2). Overall, the







Osteogenic capacity Adipogenic capacity
ALP activity
14 days
Calcium deposition Lipid vesicles
formation 14 days21 days 28 days
1 9 M ASCs < BMSCs ASCs > BMSCs ASCs < BMSCs*** ASCs < BMSCs*** ASCs > BMSCs**
2 10 M ASCs > BMSCs ASCs < BMSCs ASCs < BMSCs*** ASCs < BMSCs*** ASCs > BMSCs***
3 8 F ASCs > BMSCs*** ASCs > BMSCs ASCs < BMSCs*** ASCs > BMSCs ASCs > BMSCs***
4 10 M ASCs > BMSCs*** ASCs > BMSCs** ASCs > BMSCs*** ASCs > BMSCs*** ASCs > BMSCs***
5 12 M ASCs > BMSCs*** ASCs > BMSCs* ASCs < BMSCs*** ASCs < BMSCs ASCs > BMSCs***
6 11 M ASCs > BMSCs ASCs > BMSCs*** ASCs > BMSCs ASCs > BMSCs*** ASCs > BMSCs*
7 8 F ASCs > BMSCs ASCs < BMSCs*** ASCs < BMSCs*** ASCs < BMSCs*** ASCs > BMSCs***
8 9 M ASCs > BMSCs** ASCs < BMSCs ASCs < BMSCs* ASCs < BMSCs** ASCs > BMSCs***
9 14 F ASCs > BMSCs* ASCs < BMSCs* ASCs < BMSCs*** ASCs < BMSCs*** ASCs > BMSCs**
ALP alkaline phosphatase, ASCs adipose-derived stem cells, BMSCs bone marrow-derived stem cells, M male, F female
*p < 0.05, **p < 0.01, ***p < 0.001
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number of ASCs and BMSCs increased significantly with
time from day 3 to 14 (p < 0.001). The proliferation rate
of the stem cells from both sources was comparable at
day 3 and 7. ASCs continued to proliferate significantly
up to day 21 (p < 0.001), but proliferation reached a plat-
eau from day 14 in BMSCs. Significantly higher cel-
lular metabolic activity in ASCs compared to BMSCs
was seen at day 14 and 21 (p < 0.01), indicating higher
cell number (Fig. 2a-c). In addition, ASCs and BMSCs
demonstrated upregulated expression of PCNA that in-
creased with time from day 7 to 21. However, the
expression was significantly higher in ASCs than in
BMSCs (p < 0.001) (Fig. 2d and e). The higher metabolic
activity in ASCs relative to BMSCs at day 21 was
Fig. 1 Morphology and immunophenotype characteristics of BMSCs and ASCs. a Representative microscopic illustrations of BMSCs and ASCs.
Scale bar 100 μm. b Representative histograms from the flow cytometry analysis showing surface marker expression on BMSCs and ASCs,
monoclonal antibody control (blue) and the stained cells (red). c and d Percentage of surface markers expression, average of nine donors (c) and
in each donor (d). Each symbol represents one donor. *p < 0.05, **p < 0.01, ***p < 0.001. ASCs adipose-derived stem cells, BMSCs bone marrow-
derived stem cells
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significant in five of nine donors (p < 0.05) (Table 2).
The proliferation of ASCs and BMSCs was influenced by
donor variations (Table 3).
ASCs showed delayed ALP activity compared to BMSCs
Overall, ALP activity in BMSCs cultured in osteogenic
medium increased from day 3 to day 7, continuing to be
high up to day 14 (Fig. 3a). For ASCs cultured in osteo-
genic medium, the ALP activity increased from day 3 to
day 14, with a substantial increase in ALP activity ob-
served at day 14, which was comparable to BMSCs. ALP
activity in ASCs and BMSCs in control medium was less
than for osteogenic medium, but with BMSCs showing
more pronounced activity. The ALP assay showed variable
activity in ASCs and BMSCs among different donors,
from 1.3- to 7-fold for BMSCs and 1.5- to 5-fold for ASCs
(Fig. 3b and c). Overall, no significant difference in ALP
activity between ASCs and BMSCs at day 14 was detected.
However, ALP activity was significantly higher in ASCs
compared to BMSCs in three of nine donors (p < 0.05),
whereas ASCs in two of nine donors had significantly less
activity (p < 0.05) (Table 2). The ALP activity in ASCs and
BMSCs was influenced by donor variations (Table 3).
Comparable extracellular collagen type I was formed in
ASCs and BMSCs
IF staining images showed that collagen type I was
formed intracellularly as well as extracellularly by ASCs
and BMSCs in osteogenic medium at day 14 from all do-
nors (Fig. 3d). Only intracellular collagen type I was
observed for ASCs and BMSCs in control medium.
Overall, there was no remarkable difference in the for-
mation of extracellular collagen type I between ASCs
and BMSCs or between different donors.
Fig. 2 Proliferation of BMSCs and ASCs. a-c MTT assay at day 3, 7, 14 and 21, average of nine donors (a) and in each donor (b and c). d and e
Relative gene expression of PCNA in BMSCs and ASCs at day 7, 14 and 21, average of nine donors (d) and in each donor (e). Each symbol
represents one donor. **p< 0.01, ***p< 0.001. ASCs adipose-derived stem cells, BMSCs bone marrow-derived stem cells, MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide, PCNA proliferating cell nuclear antigen
Table 3 Effect of donor variation within ASCs and BMSCs using intra-class correlations (ICC) analysis
ASCs
ICC (95% Confidence interval)
BMSCs
ICC (95% Confidence interval)
Proliferation 0.40 (0.17–0.69) 0.48 (0.23–0.74)
Osteogenic capacity ALP activity 0.51 (0.23–0.78) 0.80 (0.58–0.92)
Calcium deposition 0.98 (0.94–0.99) 0.98 (0.94–0.99)
Adipogenic capacity Lipid vesicle formation 0.91 (0.79–0.97) 0.93 (0.83–0.97)
ICC value less than 0.40 low effect
ICC value from 0.40 to 0.74 moderate effect
ICC value from 0.75 to 1.00 high effect
ALP alkaline phosphatase, ASCs adipose-derived stem cells, BMSCs bone marrow-derived stem cells
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ASCs demonstrated delayed osteogenic capacity compared
to BMSCs
For the osteogenic differentiation at the gene level, eval-
uated by real-time qPCR, ASCs and BMSCs from the
different donors showed variable expression of the
osteogenic genes Runx2, collagen type I, ALP and osteo-
pontin (Fig. 4a and b). Overall, the expression of Runx2,
collagen type I and ALP increased from day 7 to day 14
in both ASCs and BMSCs, with significantly higher ex-
pression in BMSCs than in ASCs (p < 0.01). At day 21,
Fig. 3 ALP activity and collagen type I formation in BMSCs and ASCs. a Representative images of ALP staining of BMSCs and ASCs at day 3, 7 and 14.
Scale bar 100 μm. b and c ALP activity assay of BMSCs and ASCs at day 14, average of nine donors (b) and in each donor (c). d Representative images
of IF staining of collagen type I in BMSCs and ASCs at day 14. Scale bar 100 μm. Each symbol represents one donor. ALP alkaline phosphatase,
ASCs adipose-derived stem cells, BMSCs bone marrow-derived stem cells, DAPI 4′,6-diamidino-2-phenylindole
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Fig. 4 Osteogenic gene and protein expression, and calcium deposition in BMSCs and ASCs. a and b Relative gene expression of the osteogenic
genes Runx2, collagen type I, ALP and osteopontin in BMSCs and ASCs at day 7, 14 and 21, average of nine donors (a) and in each donor (b).
c Western blot analysis of osteopontin in BMSCs and ASCs at day 21. d Representative images after Alizarin red S staining of BMSCs and ASCs at
day 21 and 28. Scale bar 100 μm. e and f Quantification of Alizarin red S staining of BMSCs and ASCs at day 21 and 28, average of nine donors
(e) and in each donor (f). Each symbol represents one donor. **p < 0.01, ***p < 0.001. ALP alkaline phosphatase, ASCs adipose-derived stem cells,
BMSCs bone marrow-derived stem cells, Runx2 runt-related transcription factor 2
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no significant difference in the expression of these genes
was detected. The expression of these genes in BMSCs
was greatest at day 14. ASCs showed highest expression
of Runx2 and ALP at day 21. The expression of osteo-
pontin increased with time from day 7 to day 21, but
was significantly higher in BMSCs than in ASCs (p <
0.001). ASCs showed low expression of osteopontin at
all time points, in all donors. Similarly, western blot ana-
lysis at day 21 revealed higher osteopontin expression in
BMSCs compared to ASCs (Fig. 4c). For the osteogenic
differentiation evaluated by tissue-specific staining, ASCs
and BMSCs showed osteogenic capacity, confirmed by
Alizarin red S staining (Fig. 4d-f ). Overall, BMSCs cul-
tured in osteogenic medium at day 21 had significantly
more calcium deposition compared to ASCs (p < 0.001).
Although ASCs in osteogenic medium showed a remark-
able increase in calcium deposition from 21 to 28 days,
it was significantly lower than in BMSCs at day 28 (p <
0.01). A variation in calcium deposition in ASCs and
BMSCs from different donors was detected. At day 21,
ASCs showed significantly less calcium deposition than
BMSCs in seven of nine donors (p < 0.05), and signifi-
cantly more deposition in one of nine donor (p < 0.001)
(Table 2). At day 28, two of nine donors had significantly
higher calcium deposition in ASCs compared to BMSCs
(p < 0.001), whereas five of nine donors had significantly
less deposition in ASCs than in BMSCs (p < 0.01). ASCs
and BMSCs cultured in control medium showed no cal-
cium deposition. The calcium deposition in ASCs and
BMSCs was highly influenced by donor (Table 3).
ASCs showed chondrogenic capacity, but less than BMSCs
Chondrogenic differentiation at the gene level, deter-
mined by real-time qPCR, showed that the expression of
the chondrogenic gene aggrecan varied in ASCs and
BMSCs among different donors (Fig. 5a and b). Overall,
however, the expression was significantly higher in
BMSCs than in ASCs (p < 0.001), with higher expression
in BMSCs than ASCs in nine of nine donors. For chon-
drogenic differentiation, evaluated using tissue-specific
staining, ASCs and BMSCs in chondrogenic medium
formed pellets (diameter ≈ 1 mm) and showed chondro-
genic capacity, confirmed by Alcian blue staining (Fig. 5c).
After 28 days, the proteoglycan matrix of ASC and BMSC
pellets were positively stained for Alcian blue. No remark-
able difference in the cartilaginous proteoglycan matrix
formation was noted between ASCs and BMSCs from all
donors. No cartilaginous matrix was detected in ASC and
BMSC pellets cultured in control medium.
ASCs had greater adipogenic capacity than BMSCs
Adipogenic differentiation at the gene level, evaluated by
real-time qPCR, showed variation in the expression
of the adipogenic genes in ASCs and BMSCs among
different donors (Fig. 6a and b). Nevertheless, ASCs had
significantly higher expression of the adipogenic genes
LPL and PPARG compared to BMSCs at day 14
(p < 0.001), and this was observed in all donors. For adi-
pogenic differentiation, evaluated using tissue-specific
staining, ASCs and BMSCs in adipogenic medium
showed adipogenic capacity, confirmed by Oil red O
staining (Fig. 6c-e). When ASCs and BMSCs were cul-
tured in adipogenic medium, the cells started to lose
their spindle-like morphology and lipid vesicles started
to form in the cytoplasm. After 14 days, both ASCs and
BMSCs showed positive Oil red O stained intracellular
lipid vesicles. ASCs cultured in adipogenic medium
demonstrated significantly higher amounts of intracellu-
lar lipid vesicles than BMSCs (p < 0.001), a finding ob-
served in nine of nine donors (p < 0.05) (Table 2). No
Fig. 5 Chondrogenic gene expression and cartilaginous matrix formation in BMSCs and ASCs. a and b Relative gene expression of the chondrogenic
gene aggrecan in BMSCs and ASCs at day 28, average of nine donors (a) and in each donor (b). c Representative images of Alcian blue-stained
sections of BMSC and ASC pellets at day 28. Scale bar 50 μm. Each symbol represents one donor. ***p < 0.001. ASCs adipose-derived stem cells, BMSCs
bone marrow-derived stem cells
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formation of lipid vesicles was detected in ASCs and
BMSCs cultured in control medium. The lipid vesicle
formation in ASCs and BMSCs was highly influenced by
donor (Table 3).
Discussion
Adult MSCs, isolated from different connective tissues,
have a fundamental role in maintenance and regener-
ation of body tissues [30]. The density, proliferation and
differentiation capacity of MSCs derived from different
sources are crucial in cell-based therapy. In this study,
we compared the surface marker expression, prolifera-
tion and differentiation capacity of donor-matched ASCs
and BMSCs derived from young patients. This reduces
the possibility of biological variations experienced when
comparing cells from different individuals, raising ques-
tions about the reliability of the comparison [22]. ASCs
and BMSCs were derived from a homogenous age group
to avoid heterogeneity in age and to limit possible
age-related differences [28]. It has been reported that
stem cell yield, proliferation and differentiation proper-
ties of BMSCs and ASCs are negatively affected by age
[31, 32]. However, conflicting conclusions on the effects
of aging on multi-lineage differentiation capacity of
MSCs have been reported [33–35]. Different isolation
methods of BMSCs have been described, but the direct
plating method is simple and advantageous compared to
other methods [29, 36]. Isolation of ASCs from an adi-
pose tissue block is reported superior to liposuction [8,
11]. Immediately after isolation, we noted heterogeneous
cell populations, with an increase in homogeneity during
subsequent passages. Isolated ASCs and BMSCs showed
the spindle fibroblast-like cell morphology and the cap-
acity to adhere to culture flasks without notable mor-
phologic changes during expansion up to passage 5.
Flow cytometry showed a relatively similar immunopheno-
type of BMSCs and ASCs. The stem cell markers CD73,
CD90 and CD105 were highly expressed and both cell
types demonstrated low expression of the hematopoietic
markers CD34, CD45 and HLA-DR. However, the expres-
sion of the surface marker CD34 was higher in ASCs than
in BMSCs. This is in agreement with previous data, show-
ing expression of CD34 in freshly isolated ASCs that grad-
ually reduced during passaging, but was not totally lost
[37]. The morphology and immunophenotype characteris-
tics of the isolated BMSCs and ASCs were consistent with
Fig. 6 Adipogenic gene expression and lipid vesicle formation in BMSCs and ASCs. a and b Relative gene expression of the adipogenic genes
LPL and PPARG in BMSCs and ASCs at day 14, average of nine donors (a) and in each donor (b). c Representative images of Oil red O stained
BMSCs and ASCs at day 14. Scale bar 100 μm. d and e Quantification of Oil red O-stained BMSCs and ASCs at day 14, average of nine donors (d)
and in each donor (e). Each symbol represents one donor. ***p < 0.001. ASCs adipose-derived stem cells, BMSCs bone marrow-derived stem cells,
LPL lipoprotein lipase, PPARG peroxisome proliferator activated receptor gamma
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criteria proposed by the ISCT [4]. Previous findings have
demonstrated strong expression of CD49d on ASCs [38–
40], in line with our results showing a higher expression of
CD49d in ASCs compared to BMSCs in all donors. The
expression of Stro-1, a marker for cells multi-lineage po-
tential [41], has been demonstrated in both BMSCs and
ASCs [38, 39]. This was confirmed by the present study,
but BMSCs had increased expression of Stro-1 compared
to ASCs. Previous studies have reported a higher prolifera-
tion rate of BMSCs than for ASCs [12, 13]. The present
study showed that ASCs continued to increase in number
up to 21 days. The continued proliferation of ASCs may be
linked to the expression of CD34 by ASCs, as CD34 is sug-
gested to play a role in the long-term proliferation of MSCs
[42]. This is supported by other studies, reporting similar
or greater rates of proliferation of ASCs compared to
BMSCs [18, 19, 21, 22, 24, 25, 43]. The decrease in the
metabolic activity from day 14 to 21 in ASCs and BMSCs
from some donors might be explained by contact inhib-
ition of proliferation, which is the tendency of cells to stop
proliferation when reaching confluence [44]. This might be
associated with changes in cell size and cytoskeleton, even-
tually resulting in cell differentiation or apoptosis [45].
Differentiation toward different cell lineages confirms
the multi-potency of the stem cells and hence their effi-
cient therapy potentials. It has been reported that MSCs
can be expanded up to passage 4 without losing their
multi-potency [34]. This study showed multi-potency of
both ASCs and BMSCs up to passage 5. The osteogenic
differentiation of MSCs is characterized by proliferation,
matrix maturation and mineralization [46]. Collagen
type I is the most abundant protein in bone extracellular
matrix (ECM). Formation of mature collagenous ECM is
necessary for mineralization through the deposition of
minerals like calcium and phosphate [46]. In the pres-
ence of a collagen matrix, ALP enzyme activity is essen-
tial for initiation of mineralization [47]. The formation
of extracellular collagen type I, in addition to earlier high
ALP activity in BMSCs, compared to ASCs, indicate
earlier maturation of BMSCs than ASCs during osteo-
genic differentiation. ASCs might have the highest ALP
activity later than day 14. In order to compare the in
vitro osteogenic differentiation of ASCs and BMSCs
at the gene level, we compared the gene expression of
four osteogenic lineage-specific genes. Runx2 is an early
osteogenic marker essential for osteoblast differentiation
and regulates other osteogenic genes, e.g. collagen type
I, ALP and osteopontin [48, 49]. Runx2-deficient mice
are reported to lack bone formation due to absence of
osteoblasts [50]. Runx2 and collagen type I genes are
expressed during the proliferation stage of osteoblast dif-
ferentiation, but the expression declines and remains at
low level during maturation and mineralization [46, 49].
The ALP gene level increases and reaches a peak during
matrix maturation and decrease in proliferation activity,
followed by a subsequent decline during mineralization
[46]. Osteopontin is an important non-collagenous or-
ganic component of bone matrix. Low level expression
of this gene can be detected in the early stage of osteo-
genic differentiation, and the expression increases and
peaks with mineralization [46, 49]. Our results revealed
that BMSCs expressed the early osteogenic genes Runx2,
collagen type I and ALP, and the expression was highest
at day 14. In contrast, the expression of Runx2 and ALP
was highest at day 21 in ASCs. This suggests that
BMSCs stopped proliferation and started differentiation
and formation of a mature collagenous matrix at day 14.
By comparison, ASCs showed an extended proliferation
stage and delayed differentiation and mature matrix
formation. This is supported by the results from the pro-
liferation assay, showing that ASCs continued to prolif-
erate until day 21. The finding that BMSCs stopped
proliferation at day 14 supports a conclusion of earlier
osteogenic differentiation in BMSCs than in ASCs. This
conclusion was further strengthened by upregulated ex-
pression of osteopontin in BMSCs at day 21 compared
to low expression in ASCs at the gene level, and con-
firmed at the protein level for the same time point.
Moreover, results of Alizarin red S staining at day 21
showed significantly more calcium deposition for BMSCs
than ASCs, indicating earlier mineralization of the ECM.
Abundant mineralization was observed at day 28 for
ASCs. ASCs and BMSCs with higher ALP activity demon-
strated more calcium deposition than counterparts from
donors with lower ALP activity. This is in agreement with
the fact that matrix mineralization is strongly correlated
with ALP enzyme activity [27, 34]. This is also in agree-
ment with a recent report that compared donor-matched
ASCs and BMSCs, showing that BMSCs exhibited higher
in vitro osteogenic capacity than ASCs based on calcium
deposition and expression of osteogenesis-related genes
[23]. However, in that study ASCs and BMSCs were ob-
tained from donors older than 60 years. Other studies
have also shown that BMSCs have superior in vitro osteo-
genic capacity than ASCs with respect to higher ALP ac-
tivity, calcium content and expression of the early and late
osteogenic genes [21, 22, 43]. However, others have re-
ported that the in vitro osteogenic differentiation of
ASCs is superior or similar to BMSCs in terms of cal-
cium deposition and expression of osteogenesis-related
genes [18–20, 25, 51]. Moreover, the osteogenic capacity of
ASCs was enhanced under dynamic culture conditions
subjected to mechanical stimulation [52] and under culture
conditions supplemented with platelet-derived growth fac-
tor [53, 54], vitamin D3 and bone morphogenetic protein-2
(BMP-2) [55]. Aggrecan is a major component of cartilage
extracellular matrix [56]. ASCs and BMSCs differenti-
ated to a chondrogenic lineage. However, BMSCs showed
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significantly higher expression of the cartilage-specific
gene aggrecan than ASCs at day 28, similar to results that
have previously been published [12, 57]. LPL and PPARG
are highly expressed in adipose tissue, and PPARG is es-
sential for the adipocyte differentiation [58, 59]. With re-
gard to adipogenic differentiation, ASCs demonstrated
significantly higher lipid vesicle formation and expression
of the adipogenic lineage-related genes LPL and PPARG
compared to BMSCs, which is in line with previous find-
ings [60]. These findings indicate that ASCs and BMSCs
have tissue-specific differentiation potential, since higher
in vitro osteogenic and chondrogenic potential was ob-
served in BMSCs, and higher adipogenic capacity was
found in ASCs. Previous reports have also concluded that
MSCs preferentially differentiate into cells of the same tis-
sue origin [12, 60].
Our results also confirmed that the proliferation and
differentiation capacity of both ASCs and BMSCs varied
by donor. The harvested population from each bone
marrow and adipose tissue sample is not uniform and
may thus contain MSCs and cells at different differenti-
ation stages, with different proportions and with varia-
tions from donor to donor [34], not only in donors with
variations in age as previously reported [34], but also in
donors with similar age as shown in this study. A pure
population of MSCs will possibly have better prolifera-
tion and multi-lineage differentiation capacity than a
heterogeneous population consisting of MSCs and cells
at different differentiation stages. The tissue sampling
method might also affect the heterogeneity of the MSCs
population and be responsible for donor-to-donor varia-
tions, as MSCs properties varies between samples ob-
tained from the same donors at different times [27].
Unidentified factors in the medical history and the
physiological status of the donors might also contribute
to variations in the in vitro properties of ASCs and
BMSCs [27, 34]. Furthermore, epigenetic regulation fac-
tors are reported to influence the osteogenic and adipo-
genic differentiation capacity of BMSCs and ASCs. This
is based on the DNA methylation status of the main
transcription factors Runx2 and PPARG that control the
fate of MSCs [23].
Conclusions
In this study, we compared the in vitro properties of
ASCs and BMSCs derived from the same nine individ-
uals. Overall, ASCs and BMSCs were comparable with
regard to morphology and immunophenotype. ASCs
and BMSCs demonstrated multi-potency; nevertheless,
their differentiation capacity varied, with tissue-specific
differentiation seen. BMSCs were superior to ASCs in
terms of osteogenic and chondrogenic differentiation,
while ASCs had higher proliferation and adipogenic
potential. We also found that the donor is an
important factor influencing the properties of MSCs,
since properties of MSCs derived from adipose tissue
and bone marrow varied by donor. These similarities
and differences in ASCs and BMSCs should be taken
into consideration when planning stem cell-based clin-
ical therapy.
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